<DOC>
	<DOCNO>NCT01732198</DOCNO>
	<brief_summary>Evaluate safety tolerability single booster dose NU300 , co-administered Prevnar 13® 28 day period follow injection compare single booster ACTHIB co-administered Prevnar 13® 28 day period follow injection . Evaluate immunogenicity , determine anti-PRP polysaccharide response , single booster dose NU300 co-administered Prevnar 13® compare single booster dose ActHIB® co-administered Prevnar 13® . Evaluate individual IgG antibody quantitative response 13 antigen Prevnar 13® follow NU300 co-administration Prevnar 13® compare IgG antibody response pneumococcal polysaccharide follow ActHIB® co-administration Prevnar 13® 28 day follow injection .</brief_summary>
	<brief_title>A Phase 2 , Multicenter , Open-label Study Assess Immunogenicity Investigational Hib Vaccine ( NU300 ) Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Written inform consent obtain parent guardian subject 2 . Male female subject 1215 month age time booster vaccination , previously receive complete primary vaccination series license Hib product Prevnar 13® accordance FDA approve label . 3 . Subjects investigator believe parent/guardian comply requirement protocol 4 . Subjects free obvious health problem establish medical history clinical examination enter study 1 . Previous booster vaccination Hib and/or Prevnar 13® 2 . Any confirmed suspected Haemophilus influenzae pneumococcal illness . 3 . Administration vaccine foreseen study protocol period start 30 day end 28 day administration study vaccine ( blood draw Visit 2 ) . 4 . Chronic administration immunosuppressant immunemodifying drug within 30 day prior dose study . 5 . Any confirmed suspected immunosuppressive immunodeficient condition base medical history and/or clinical examination . 6 . Early preterm birth ( delivery 32 week ) . 7 . Major congenital defect serious chronic disease , serious condition include history seizure , apnea , etc . 8 . Concurrent participation another clinical study time study period within previous 6 month subject expose investigational noninvestigational product ( pharmaceutical product , formula , device ) 9 . Presence moderate severe illness without fever time vaccination ( fever define temperature ≥ 38.0C [ 100.4F ] ) . 10 . Known history thrombocytopenia coagulation disorder . 11 . Known hypersensitivity component vaccine . 12 . Known hypersensitivity latex . 13 . The subject unable provide adequate blood draw immunogenicity assay , safety panel Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>